Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory

International Journal of Antimicrobial Agents

Volumn 28, Issue 6, 2006, Pages 574-577

  Soltani, Mehnam ^a   Tobin, Caroline M ^a   Bowker, Karen E ^a   Sunderland, Julie ^a   MacGowan, Alasdair P ^a   Lovering, Andrew M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Antifungal; Neonates; Serum; Toxicity

Indexed keywords

FLUCYTOSINE;

ARTICLE; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MYCOSIS; NEWBORN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FLUCYTOSINE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; LABORATORIES; MYCOSES; REFERENCE STANDARDS;

EID: 33751197288     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.013     Document Type: Article

References (25)

1. Baley J.E., Kliegman R.M., and Fanaroff A.A. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 73 (1984) 144-152
2. Baley J.E., and Silverman R.A. Systemic candidiasis: cutaneous manifestations in low birth weight infants. Pediatrics 82 (1988) 211-215
3. Faix R.G., Kovarik S.M., Shaw T.R., and Johnson R.V. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 83 (1989) 101-107
4. Gonzales C.E., Shetty D., Lewis L.L., Mueller B.U., Pizzo P.A., and Walsh T.J. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 15 (1996) 769-800
5. Chanock S.J., and Walsh T.J. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transplant 18 Suppl. 3 (1996) S15-S20
6. Miniero R., Nesi F., Vai S., et al. Cryptococcal meningitis following a thrombotic microangiopathy in an unrelated donor bone marrow transplant recipient. Pediatr Hematol Oncol 14 (1997) 469-474
7. Frattarelli D.A., Reed M.D., Giacoia G.P., and Aranda J.V. Antifungals in systemic neonatal candidiasis. Drugs 64 (2004) 949-968
8. Bennett J.E. Flucytosine. Ann Intern Med 86 (1977) 319-322
9. Mauceri A.A., Cullen S.I., Vandevelde A.G., and Johnson J.E. Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol 109 (1974) 873-876
10. Kaur R., Rawat D., Kakkar M., Monga R., and Sharma V.K. Cryptococcal meningitis in pediatric AIDS. J Trop Pediatr 49 (2003) 124-125
11. Stamm A.M., Diasio R.B., Dismukes W.E., et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 83 (1987) 236-242
12. Rao H.K., and Myers G.J. Candida meningitis in the newborn. South Med J 72 (1979) 1468-1471
13. Brandt M.E., Pfaller M.A., Hajjeh R.A., et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45 (2001) 3065-3069
14. Marr K. Combination antifungal therapy: where are we now, and where are we going?. Oncology 18 13 Suppl. 7 (2004) 24-29
15. Scholer H.J. Flucytosine. In: Speller D.C.E. (Ed). Chemotherapy (1977), Wiley & Sons, Chichester, UK
16. Song J.C., and Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs 6 (2005) 170-177
17. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 73 (1998) 1205-1225
18. Benson J.M., and Nahata M.C. Clinical use of systemic antifungal agents. Clin Pharm 7 (1998) 424-438
19. Vermes A., Kuijper E.J., Guchelaar H.J., and Dankert J. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy 49 (2003) 17-23
20. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 20 (1994) 522-528
21. Sato Y. Pharmacokinetics of antibiotics in neonates. Acta Paediatr Jpn 39 (1997) 124-131
22. Baley J.E., Meyers C., Kliegman R.M., Jacobs M.R., and Blumer J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-flucytosine in neonates. J Pediatr 116 (1990) 791-797
23. Joerger M., Schellens J.H., and Beijnen J.H. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp Clin Pharmacol 26 (2004) 531-545
24. Schonebeck J., Polak A., Fernex M., and Scholer H.J. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 18 (1973) 321-336
25. Kapur G., Mattoo T., and Aranda J.V. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 28 (2004) 132-140